CBio's heat shock protein progressing for arthritis
This article was originally published in Scrip
Executive Summary
CBio is around halfway to recruiting the 150 patients it needs for a new Phase IIa trial with a recombinant chaperonin 10 therapy for rheumatoid arthritis. The placebo-controlled study began in June at sites in Australia and New Zealand and is enrolling patients with active disease despite current therapy. The heat shock protein is thought to inhibit toll-like receptor signalling to prevent the over-expression of multiple pro-inflammatory cytokines, reducing immune cell activation and inflammation. The private Australian bioventure originally acquired rights from the University of Queensland and has also completed Phase IIa trials in psoriasis and multiple sclerosis.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.